{"title":"从 NAFLD 到 MASLD 不断发展的肝脏疾病见解","authors":"Xiude Fan, Yongfeng Song, Jiajun Zhao","doi":"10.1016/j.tem.2024.02.012","DOIUrl":null,"url":null,"abstract":"The recent renaming of ‘non-alcoholic fatty liver disease’ (NAFLD) to ‘metabolic dysfunction-associated steatotic liver disease’ (MASLD) emphasizes metabolic dysfunction in steatotic liver disease and advocates for tailored, comprehensive treatment strategies, driving forward the development of personalized care and innovative therapeutic approaches.","PeriodicalId":23301,"journal":{"name":"Trends in Endocrinology & Metabolism","volume":"98 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-02-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Evolving liver disease insights from NAFLD to MASLD\",\"authors\":\"Xiude Fan, Yongfeng Song, Jiajun Zhao\",\"doi\":\"10.1016/j.tem.2024.02.012\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The recent renaming of ‘non-alcoholic fatty liver disease’ (NAFLD) to ‘metabolic dysfunction-associated steatotic liver disease’ (MASLD) emphasizes metabolic dysfunction in steatotic liver disease and advocates for tailored, comprehensive treatment strategies, driving forward the development of personalized care and innovative therapeutic approaches.\",\"PeriodicalId\":23301,\"journal\":{\"name\":\"Trends in Endocrinology & Metabolism\",\"volume\":\"98 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-02-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Trends in Endocrinology & Metabolism\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.tem.2024.02.012\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Trends in Endocrinology & Metabolism","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.tem.2024.02.012","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Evolving liver disease insights from NAFLD to MASLD
The recent renaming of ‘non-alcoholic fatty liver disease’ (NAFLD) to ‘metabolic dysfunction-associated steatotic liver disease’ (MASLD) emphasizes metabolic dysfunction in steatotic liver disease and advocates for tailored, comprehensive treatment strategies, driving forward the development of personalized care and innovative therapeutic approaches.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
